Cat. No.: HY-111338

Tacrine

8 Cited Publications

Avis client

Based on 8 publication(s) in Google Scholar

Tacrine is an effective oral acetylcholine (AChE) inhibitor (IC₅₀ = 109 nM) and also acts as an active substrate for CYP1A2. Tacrine can restore cognitive dysfunction in elderly rats. Tacrine can cause liver toxicity and is used in research related to Alzheimer's disease.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.10%
CAS No.: 321-64-2
Formule: C₁₃H₁₄N₂
Masse moléculaire:198.27

Stockage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Tacrine Chemical Structure

CAS No.: 321-64-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vivo
- Essai clinique
Chemical Information
Publications (8)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

AChE

109 nM (IC₅₀)

Voir tous les produits spécifiques à Isoform Cholinesterase (ChE) :

AChE
BChE

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	>100 μM Compound: Tacrine	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 28728108]
C6	IC₅₀	450.7 μM Compound: Tacrine	Cytotoxicity against rat C6 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against rat C6 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32904099]
Cerebral cortex neuron	EC₅₀	1.33 μM Compound: Tacrine	Neuroprotective activity in 20 uM rotenone and 10 uM oligomycin-treated Wistar rat primary cortical neurons assessed as increase in cell viability after 24 hrs by XTT assay Neuroprotective activity in 20 uM rotenone and 10 uM oligomycin-treated Wistar rat primary cortical neurons assessed as increase in cell viability after 24 hrs by XTT assay	[PMID: 22795665]
CHO-K1	IC₅₀	248 μM Compound: THA; 3	Cytotoxicity against CHOK1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against CHOK1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30851693]
CHO-K1	IC₅₀	303 μM Compound: THA	Cytotoxicity against CHO-K1 cells incubated for 24 hrs by MTT assay Cytotoxicity against CHO-K1 cells incubated for 24 hrs by MTT assay	[PMID: 38218127]
HBL-100	GI₅₀	50 μM Compound: Tacrine	Antiproliferative activity against human HBL100 cells after 48 hrs by SRB assay Antiproliferative activity against human HBL100 cells after 48 hrs by SRB assay	[PMID: 28728108]
HEK293	IC₅₀	122 nM Compound: Tacrine	Inhibition of cerebral human recombinant AchE expressed in HEK293 cells using acetylthiocholine iodide as substrate preincubated for 10 mins measured after 15 mins of substrate addition by Ellman's method Inhibition of cerebral human recombinant AchE expressed in HEK293 cells using acetylthiocholine iodide as substrate preincubated for 10 mins measured after 15 mins of substrate addition by Ellman's method	[PMID: 22023459]
HEK293	IC₅₀	0.13 μM Compound: Tacrine	Inhibition of recombinant human AChE expressed in HEK293 cells using acetylthiocholine iodide as substrate pretreated for 5 mins followed by substrate addition measured after 5 mins by spectrophotometry based Ellman method Inhibition of recombinant human AChE expressed in HEK293 cells using acetylthiocholine iodide as substrate pretreated for 5 mins followed by substrate addition measured after 5 mins by spectrophotometry based Ellman method	[PMID: 27918993]
HEK293	IC₅₀	21.72 μM Compound: Tacrine	Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay	[PMID: 28230985]
HEK293	IC₅₀	412 nM Compound: 1	Inhibition of human recombinant AChE expressed in HEK293 cells using acetylcholine iodide as substrate preincubated with enzyme for 20 mins followed by substrate addition and measured after 5 mins by Ellman's method Inhibition of human recombinant AChE expressed in HEK293 cells using acetylcholine iodide as substrate preincubated with enzyme for 20 mins followed by substrate addition and measured after 5 mins by Ellman's method	[PMID: 31376562]
HEK293	IC₅₀	0.15 μM Compound: Tacrine	Inhibition of recombinant human AChE expressed in HEK293 cells using acetylthiocholine iodide as substrate preincubated for 5 mins before substrate addition measured after 10 mins by Ellman's method Inhibition of recombinant human AChE expressed in HEK293 cells using acetylthiocholine iodide as substrate preincubated for 5 mins before substrate addition measured after 10 mins by Ellman's method	10.1039/C1MD00221J
HeLa	GI₅₀	51 μM Compound: Tacrine	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 28728108]
HepG2	IC₅₀	98.73 μM Compound: Tacrine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24794747]
HepG2	IC₅₀	19.37 μM Compound: 1	Hepatotoxicity in human HepG2 cells assessed as cell viability after 24 hrs by MTT assay Hepatotoxicity in human HepG2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 26503905]
HepG2	EC₅₀	179 μM Compound: Tacrine	Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability by MTT assay Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 27128182]
HepG2	IC₅₀	17.9 μg/mL Compound: Tacrine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28189905]
HepG2	IC₅₀	168.47 μM Compound: THA; Tacrine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29533874]
HepG2	IC₅₀	111 μM Compound: 1	Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay	[PMID: 30108847]
HepG2	IC₅₀	98 μM Compound: Tacrine	Cytotoxicity against human HepG2 cell assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cell assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30771604]
HepG2	IC₅₀	190 μM Compound: THA; 3	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30851693]
HepG2	IC₅₀	114.9 μM Compound: Tacrine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32904099]
HepG2	IC₅₀	168.47 μM Compound: THA	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33984470]
HepG2	IC₅₀	144826 nM Compound: Tacrine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34530383]
J774.1	IC₅₀	>100 μM Compound: 1a; Tacrine	Cytotoxicity against mouse J774.1 cells after 24 hrs by AlamarBlue based cytotoxicity assay Cytotoxicity against mouse J774.1 cells after 24 hrs by AlamarBlue based cytotoxicity assay	[PMID: 27316542]
J774.1	IC₅₀	>100 μM Compound: 1a	Cytotoxicity against mouse J774.1 cells after 24 hrs by alamar blue assay Cytotoxicity against mouse J774.1 cells after 24 hrs by alamar blue assay	[PMID: 28698054]
Primary neuron	IC₅₀	7.87 μM Compound: Tacrine	Toxicity in mouse neuronal cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Toxicity in mouse neuronal cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30771604]
Sf21	IC₅₀	>1000 μM Compound: Tacrine	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	>1000 μM Compound: Tacrine	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
SH-SY5Y	IC₅₀	120 μM Compound: Tac	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29541355]
SH-SY5Y	IC₅₀	0.5 μM Compound: 1; THA	Inhibition of human SH-SY5Y cell lysate acetylcholinesterase using acetylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition by Ellman's method Inhibition of human SH-SY5Y cell lysate acetylcholinesterase using acetylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition by Ellman's method	[PMID: 30744931]
SH-SY5Y	IC₅₀	165 μM Compound: Tacrine	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by crystal violet staining based analysis Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by crystal violet staining based analysis	[PMID: 38401458]
SW1573	GI₅₀	50 μM Compound: Tacrine	Antiproliferative activity against human SW1573 cells after 48 hrs by SRB assay Antiproliferative activity against human SW1573 cells after 48 hrs by SRB assay	[PMID: 28728108]
Sympathetic neuron	IC₅₀	30 μM Compound: 4	Ability to inhibit after-hyperpolarization (AHP) in cultured rat sympathetic neurons. (number of neurons tested, n=3). Insufficient activity at this concentration Ability to inhibit after-hyperpolarization (AHP) in cultured rat sympathetic neurons. (number of neurons tested, n=3). Insufficient activity at this concentration	[PMID: 7861407]
T47D	GI₅₀	46 μM Compound: Tacrine	Antiproliferative activity against human T47D cells after 48 hrs by SRB assay Antiproliferative activity against human T47D cells after 48 hrs by SRB assay	[PMID: 28728108]
Vero	IC₅₀	168.9 μM Compound: Tacrine	Cytotoxicity against monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32904099]
WiDr	GI₅₀	34 μM Compound: Tacrine	Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay	[PMID: 28728108]

In Vivo

Tacrine (0.3-3 mg/kg, orally, single dose) increases extracellular acetylcholine levels in rat hippocampus and improves behavioral function^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

6- and 22-24-month-old rats^[1]
Dosage:

0.3, 1, 3 mg/kg; single dose
Administration:

Oral
Result:

Doubled the extracellular acetylcholine levels in young rats' hippocampal cells and increased it six times in older rats, improving discrimination ability, restoring passive avoidance conditioning responses, and enhancing behavioral function.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 321-64-2
Appearance Solid
Masse moléculaire 198.27
Formule C₁₃H₁₄N₂
Color Off-white to light yellow
SMILES

NC1=C2CCCCC2=NC3=CC=CC=C31
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (8)

All

Sort by:

Journal Impact Factor

Cell Death Dis

A fragment of cell adhesion molecule L1 reduces amyloid-β plaques in a mouse model of Alzheimer's disease. [Abstract]

2022 Jan 10;13(1):48. PMID: 35013124
Drug Deliv

A surrogate barrier model for high-throughput blood-brain barrier permeability prediction: integrating LLC-PK1-MOCK/MDR1 Cells and lysosomal trapping correction. [Abstract]

2025 Dec 31;32(1):2585612. PMID: 41307200
J Med Chem

Fluorocyclopropyl-Containing Tacrine Derivatives as Potent and Selective Dual CDK2/CDK9 Inhibitors for the Treatment of Colorectal Cancer. [Abstract]

2025 Nov 27;68(22):24326-24357. PMID: 41239996
Eur J Med Chem

Design, synthesis and biological evaluation of carbamate derivatives incorporating multifunctional carrier scaffolds as pseudo-irreversible cholinesterase inhibitors for the treatment of Alzheimer's disease. [Abstract]

2024 Feb 5:265:116071. PMID: 38157596
J Enzyme Inhib Med Chem

Design, synthesis and evaluation of OA-tacrine hybrids as cholinesterase inhibitors with low neurotoxicity and hepatotoxicity against Alzheimer's disease. [Abstract]

2023 Dec;38(1):2192439. PMID: 36950955
Bioorg Chem

Design, synthesis, and biological evaluation of novel donepezil-tacrine hybrids as multi-functional agents with low neurotoxicity against Alzheimer's disease. [Abstract]

2024 Feb:143:107010. PMID: 38056387
J Neurochem

The Tacrine-Induced Endoplasmic Reticulum Stress in AChE-Expressed Cells Leads to Improper Assembly and Transport of the Oligomeric Enzyme: Reversal by Trehalose. [Abstract]

2025 Aug;169(8):e70178. PMID: 40762084
Front Neurosci

Adhesion Molecule L1 Agonist Mimetics Protect Against the Pesticide Paraquat-Induced Locomotor Deficits and Biochemical Alterations in Zebrafish. [Abstract]

2020 May 28:14:458. PMID: 32547358

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (504.36 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.0436 mL

25.2181 mL

50.4363 mL

5 mM

1.0087 mL

5.0436 mL

10.0873 mL

10 mM

0.5044 mL

2.5218 mL

5.0436 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (12.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 2.5 mg/mL (12.61 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (277 KB)
SDS (483 KB)
- English - EN (483 KB)
- Français - FR (483 KB)
- Deutsch - DE (483 KB)
- Norwegian - NO (483 KB)
- Español - ES (483 KB)
- Swedish - SV (483 KB)
- Italian - IT (483 KB)
- Korean - KR (483 KB)
- Portuguese - PT (483 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. C Scali, et al. Tacrine administration enhances extracellular acetylcholine in vivo and restores the cognitive impairment in aged rats. Pharmacol Res. 1997 Dec;36(6):463-9. [Content Brief]

[2]. Patocka J, et al. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease. Curr Drug Metab. 2008;9(4):332-335. [Content Brief]

[3]. Bhatt S, et al. Assessment of the CYP1A2 Inhibition-Mediated Drug Interaction Potential for Pinocembrin Using In Silico, In Vitro, and In Vivo Approaches. ACS Omega. 2022;7(23):20321-20331. Published 2022 Jun 2. [Content Brief]

[4]. Romero A, et al. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. Bioorg Med Chem Lett. 2013;23(7):1916-1922. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.0436 mL	25.2181 mL	50.4363 mL	126.0907 mL
	5 mM	1.0087 mL	5.0436 mL	10.0873 mL	25.2181 mL
	10 mM	0.5044 mL	2.5218 mL	5.0436 mL	12.6091 mL
	15 mM	0.3362 mL	1.6812 mL	3.3624 mL	8.4060 mL
	20 mM	0.2522 mL	1.2609 mL	2.5218 mL	6.3045 mL
	25 mM	0.2017 mL	1.0087 mL	2.0175 mL	5.0436 mL
	30 mM	0.1681 mL	0.8406 mL	1.6812 mL	4.2030 mL
	40 mM	0.1261 mL	0.6305 mL	1.2609 mL	3.1523 mL
	50 mM	0.1009 mL	0.5044 mL	1.0087 mL	2.5218 mL
	60 mM	0.0841 mL	0.4203 mL	0.8406 mL	2.1015 mL
	80 mM	0.0630 mL	0.3152 mL	0.6305 mL	1.5761 mL
	100 mM	0.0504 mL	0.2522 mL	0.5044 mL	1.2609 mL

Keywords

Tacrine

8 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Tacrine

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Chinese Baijiu Compound Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Tacrine

Voir tous les produits spécifiques à Isoform Cholinesterase (ChE)

Activité biologique

Chemical Information

Publications (8)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Tacrine

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Chinese Baijiu Compound Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Tacrine

Voir tous les produits spécifiques à Isoform Cholinesterase (ChE)

Activité biologique

Chemical Information

Publications (8)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Tacrine Related Classifications

HY-111338 Related Classifications